安罗替尼联合白蛋白紫杉醇化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响

Impact of Anlotinib Combined with Albumin Paclitaxel Chemotherapy on Serum Tumor Markers in Patients with Advanced Non-Small Cell Lung Cancer

目的探讨安罗替尼联合白蛋白紫杉醇化疗治疗晚期非小细胞肺癌(NSCLC)患者的临床效果。方法82例晚期NSCLC患者按治疗方法的不同分为两组,对照组40例给予白蛋白紫杉醇化疗治疗,观察组42例给予安罗替尼联合白蛋白紫杉醇化疗治疗,比较两组的疗效、血清肿瘤标志物水平以及不良反应。结果观察组的治疗总有效率显著高于对照组(P<0.05)。治疗后,观察组的血清CA125、CEA、CYFRA21-1水平均显著低于对照组(P<0.05)。观察组的各项不良反应发生率均显著低于对照组(P<0.05)。结论安罗替尼联合白蛋白紫杉醇化疗治疗晚期NSCLC效果显著,可有效降低肿瘤标志物水平,安全性高。

Objective To explore the clinical effect of anlotinib combined with albumin paclitaxel chemotherapy in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods 82 patients with advanced NSCLC were divided into two groups according to different treatment methods.40 cases in the control group were treated with albumin paclitaxel chemotherapy,and 42 cases in the observation group were treated with anlotinib combined with albumin paclitaxel chemotherapy.The efficacy,levels of serum tumor markers and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group(P<0.05).After treatment,the levels of serum CA125,CEA and CYFRA21-1 in the observation group were significantly lower than those in the control group(P<0.05).The incidences of adverse reactions in the observation group were significantly lower than those in the control group(P>0.05).Conclusions Anlotinib combined with albumin paclitaxel chemotherapy in the treatment of advanced NSCLC has significant effect and high safety,and can effectively reduce the level of serum tumor markers.